

Posters

P-002	Tania	Bildstein	United Kingdom	Efficacy and Safety of Ustekinumab in paediatric Inflammatory Bowel Disease: a quaternary centre experience
P-003	Michael	Bording-Jorgensen	Canada	Short-Chain Fatty Acids Affect Epithelial and Macrophage Response to the Pediatric IBD-associated Pathobiont <i>Bacteroides fragilis</i>
P-004	Caterina	Strisciuglio	Italy	Role of miRNAs in Children with Crohn's disease in Infliximab Treatment
P-005	Giulia	Catassi	Italy	Histologic findings at diagnosis as predictive markers of clinical outcome in pediatric Ulcerative Colitis
P-006	Caterina	Strisciuglio	Italy	Faecal S100A12 as a non-invasive marker in Inflammatory Bowel Disease
P-008	Wael	El-Matary	Canada	Gut microbiome abundance, diversity, and metabolic changes are correlated with sleep efficiency and disease phenotype in paediatric inflammatory bowel disease
P-013	Miikka	Höyhty	Finland	Fecal microbiota in orofacial granulomatosis
P-015	Natsuki	Ito	Japan	Genetic and epigenetic analyses of the Japanese very early onset IBD
P-016	Aleksandra	Jatkowska	United Kingdom	Faecal pH and short-chain fatty acids are objective and discriminatory biomarkers of compliance to exclusive enteral nutrition.
P-017	Aleksandra	Jatkowska	United Kingdom	Partial enteral nutrition use for Crohn's disease management: a systematic review
P-018	Eva	Karaskova	Czech Republic	Circulating levels of WISP-1 (Wnt1-Inducible Signaling Pathway Protein 1) and other selected adipokines in children with inflammatory bowel disease

Posters

P-019	Filippo	Mondi	Italy	Impact of exclusive enteral nutrition vs. steroid induction therapy on transmural healing in paediatric patients with Crohn Disease
P-020	Gili	Focht	Israel	Utility of the Endoscopic Healing Index in a cohort of pediatric Crohn's Disease
P-021	Anna-Maria	Schneider	Austria	Hydrogen sulfide metabolizing enzymes in the intestinal mucosa in pediatric and adult inflammatory bowel disease
P-023	Richard	Strauss	United States	Feasibility of Using Real-World Data from the ImproveCareNow Registry to Examine the Efficacy of Ustekinumab for Paediatric Crohn's Disease
P-025	Sheri	Volger	United States	VALIDATION OF THE SIMPLIFIED ENDOSCOPIC MUCOSAL ASSESSMENT OF CROHN'S DISEASE (SEMA-CD): A NOVEL ENDPOINT TO ASSESS ENDOSCOPIC IMPROVEMENT WITH REAL WORLD DATA
P-026	Konstantinos	Gerasimidis	United Kingdom	The Effect of Exclusive Enteral Nutrition on Inflammation Related Proteins in Paediatric Patients with Crohn's Disease
P-027	Magdalena	Wlazlo	Poland	Dual Biologic in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series.
P-029	Ruqaiya	AL Jashmi	United Kingdom	The musculoskeletal manifestations of paediatric inflammatory bowel disease (IBD): the GOSH experience
P-030	Sara	Azevedo	Portugal	Patient- Reported-Outcome-Measurement Information System (PROMIS) in Paediatric Inflammatory Bowel Disease- Preliminary study of clinical usefulness
P-032	Allison	Bihari	Canada	Predicting Transition Success in Young Adults with Inflammatory Bowel Disease: a Single Site Retrospective Cohort Study
P-033	Tania	Bildstein	United Kingdom	Effective treatment with Ustekinumab in a 3-year-old with chronic granulomatous disease-related colitis: a case report

Posters

P-034	Luca	Bosa	Italy	Sugar Intestinal Permeability Test correlates with paediatric Crohn's disease phenotype and activity and predicts the development of a stricturing behaviour
P-035	Marleen	Bouhuys	Netherlands	De-escalation of anti-tumour necrosis factor agents and reduction of adverse effects: a systematic review
P-037	Laurie S.	Conklin	United States	Biologic Response and Remission in Paediatric-Onset and Adult-Onset Inflammatory Bowel Disease
P-039	Marta	Tavares	Portugal	Surgery's role in paediatrics inflammatory bowel disease: our 12-years' experience
P-040	Marta	Tavares	Portugal	Perianal pediatric Chron's disease - an earlier call to the Pediatric Surgeon
P-042	Eileen	Crowley	Canada	Recommendations for Standardizing Magnetic Resonance Imaging-based Evaluation of Perianal Fistulizing Disease Activity in Pediatric Crohn's Disease Clinical Trials
P-044	Eileen	Crowley	Canada	Heterogeneity in Efficacy and Safety Endpoints for Pediatric Clinical Trials in Inflammatory Bowel Disease: A Need for Harmonization
P-045	Manfredi	D'Affitto	United Kingdom	The Efficacy and Safety of Oral Vancomycin in the Treatment of Paediatric IBD: A Single Centre Retrospective Study
P-046	Colette	Deslandres	Canada	Early proactive drug monitoring strategy of infliximab as monotherapy in pediatric inflammatory bowel disease is associated with good sustained clinical remission
P-047	JUAN JOSE	DIAZ	Spain	Nutritional treatment with a specific exclusion diet plus a polymeric formula is comparable to standard nutritional therapy in newly diagnosed Crohn's disease children.
P-048	Valeria	Dipasquale	Italy	Enhanced recovery care versus traditional care after surgery in pediatric patients with inflammatory bowel disease: a retrospective case-control study

Posters

P-049	Nabil	El-Lababidi	Czech Republic	Adalimumab use in paediatric inflammatory bowel disease: A single centre real-life experience
P-050	Nabil	El-Lababidi	Czech Republic	Crohn's disease exclusion diet: A single centre real-life experience.
P-051	Nabil	El-Lababidi	Czech Republic	Anti-TNF-α in paediatric inflammatory bowel disease: A single centre real-life experience
P-052	Wael	El-Matary	Canada	Indirect and out-of-pocket disease-associated costs in paediatric inflammatory bowel disease: a nation-wide cross-sectional analysis from the Canadian Paediatric IBD Network
P-053	Nikolina	Birimac	Netherlands	New EUROKIDS registry for diagnosis of paediatric IBD
P-055	Sebastiano	Forgia	Germany	Prevalence and incidence of fistulising Crohn's disease and associated treatment patterns in paediatric patients in the United States
P-056	Dewruwan	Gammanpila	Australia	A prospective cross-sectional mixed-methods study evaluating dietary modifications in children with Inflammatory Bowel Disease.
P-057	Imaan	Hirji	United Kingdom	Prevalence of Growth Restriction in a Contemporary Paediatric Inflammatory Bowel Disease Cohort
P-058	Ondrej	Hradsky	Czech Republic	Sustainability in paediatric patients with Crohn's disease – analysis from Czech national registry of biologic treatment (CREdIT)
P-059	Alexandra	Hudson	Canada	Pediatric Patient and Caregiver Satisfaction with the use of Transabdominal Bowel Ultrasound in the Assessment of Inflammatory Bowel Disease
P-060	Takashi	Ishige	Japan	Treatments received within 6 months after diagnosis of Pediatric Crohn's Disease: Analysis of the Japanese Pediatric Inflammatory Bowel Disease Registry.

Posters

P-061	Jasmijn Z.	Jagt	Netherlands	Real-Life Experience of Anti-drug Antibodies Against Anti-TNF Agents at Two Tertiary Care Paediatric Inflammatory Bowel Disease Centres
P-062	Muhammad Shahzad	Shabir	Australia	Suboptimal vaccination coverage and serological screening in West Australian children with Inflammatory bowel disease- an opportunity for improvement.
P-063	María Clara	Jijón Andrade	Spain	Safety and efficacy of granulocyte-monocyte apheresis in paediatric ulcerative colitis
P-064	Kelsey D J	Jones	United Kingdom	Phosphomannumutase 2 (PMM2) variants leading to Hyperinsulinism-Polycystic Kidney Disease are associated with Early-Onset Inflammatory Bowel Disease and gastric antral foveolar hyperplasia
P-066	Zilola	Khadjieva	Uzbekistan	Usefulness of 5-ASA in the maintenance treatment of pediatric Crohn disease
P-067	Yeong Eun	Kim	Republic of Korea	Epidemiologic Study of Paediatric Inflammatory Bowel Disease according to Age Subclassification: Nationwide Population-Based Study in Korea
P-068	Martina	Klemenak	Slovenia	The incidence of the paediatric inflammatory bowel disease and the use of biological treatment have increased during the Covid-19 pandemic in NE Slovenia
P-070	Renz C W	Klomberg	Netherlands	Anti-tumor necrosis factor alpha therapy withdrawal in paediatric patients with inflammatory bowel disease: a prospective observational study
P-072	Denitza	Kofinova	Bulgaria	Mucocutaneous Manifestations in Paediatric Patients with Inflammatory Bowel Disease
P-073	Denitza	Kofinova	Bulgaria	Treatment with Vedolizumab in Bulgarian Paediatric Patients with Inflammatory Bowel Disease - Experience of a Referral Centre
P-076	Tereza	Lerchova	Czech Republic	Prediction of relapse on thiopurine treatment: the Paediatric IBD Porto group of ESPGHAN study

Posters

P-079	Nurit	Loberman Nachum	Israel	The Effectiveness of QingDai in children with active Ulcerative Colitis
P-080	Inés	Loverdos	Spain	EPIDEMIOLOGY AND CHANGES IN PHARMACOLOGIC TREATMENT OF PEDIATRIC INFLAMMATORY BOWEL DISEASE OVER 10 YEARS IN CATALONIA
P-082	Ramit	Magen Rimon	Israel	No-treatment management may be a good option for a few children with ulcerative colitis - a nationwide study from the epi-IIRN
P-083	Rohan	Malik	India	Pediatric Inflammatory bowel disease : Initial experience from a single centre in North India
P-084	Ola	Olén	Sweden	Earnings in adult age in patients with childhood-onset inflammatory bowel disease: a nationwide population-based cohort study
P-085	Marianne	Malmquist	Sweden	Frequent occurrence of perianal disease and granuloma formation in patients with Crohn's disease and concomitant orofacial granulomatosis 5 years after diagnosis
P-087	Manar	Matar	Israel	Intestinal ultrasound role in the management of pediatric inflammatory bowel disease: A prospective longitudinal cohort study
P-088	Monika	Meglicka	Poland	Effect of the Crohn's disease exclusion diet (CDED) on the fecal calprotectin level in children with active Crohn's disease.
P-091	Natalia	Mouratidou	Sweden	Change of subtype and progression of childhood-onset inflammatory bowel disease.
P-092	Judwin	Ndzo	United Kingdom	Thiopurine-Induced Pancreatitis in PIBD – Experience at a single centre.
P-093	Takuya	Nishizawa	Japan	Analysis of the actual use of enteral nutrition therapy for childhood-onset Crohn's disease using the Japanese Paediatric Inflammatory Bowel Disease Registry: final report.

Posters

P-095	Laura María	Palomino Pérez	Spain	Analysis of the serologic response to COVID-19 Vaccination in pediatric Inflammatory Bowel Disease
P-096	Laura María	Palomino Pérez	Spain	VIDEO CAPSULE ENDOSCOPY IN PEDIATRIC INFLAMMATORY BOWEL DISEASE: INDICATIONS, FINDINGS AND OTHER RELATED OUTCOMES
P-097	Arjun	Parihar	India	Multi-linguistic validation of the IMPACT-III instrument to assess the quality of life of Indian children with inflammatory bowel disease
P-098	Laura	Gianolio	Italy	Modification of anthropometric parameters and body composition during anti-TNFα treatment in paediatric inflammatory bowel disease
P-099	Edward	Giles	Australia	What do young people with inflammatory bowel disease, their parents/carers and clinicians value for inclusion in a disease-specific electronic medical record?
P-100	Charanya	Rajan	Singapore	Prevalence, management and outcome of mycobacterium tuberculosis infections in paediatric patients with inflammatory bowel disease in Singapore: A 13-year review
P-101	Sunita	Rajani	United Kingdom	Impact of induction therapies on anthropometric indices in luminal Crohns disease
P-102	Sunita Amar	Rajani	United Kingdom	Large Vessel Vasculitis as extraintestinal manifestation (EIM) of Inflammatory Bowel Disease (IBD)
P-103	Vivek	Rajasekaran	New Zealand	Paediatric Inflammatory Bowel Disease in South Asian children in New Zealand: Increasing in incidence with a More Severe Phenotype
P-104	Laura	Gianolio	Italy	Dermatological manifestations in paediatric inflammatory bowel disease: a single centre experience in Northern Italy
P-105	Marta	Tavares	Portugal	Vaccination in Pediatric Inflammatory Bowel Disease – experience of a Portuguese tertiary center

Posters

P-106	Petra	Riznik	Slovenia	Diagnostic delays in paediatric inflammatory bowel disease and the impact of Covid-19 pandemic on the incidence of the disease in North-eastern Slovenia
P-107	Nisreen	Saifuddin	United Kingdom	A review of the factors affecting remission rates in a tertiary paediatric IBD cohort
P-108	Mohana	Sathiaseelan	Australia	Faecal calprotectin remission within the first year of diagnosis is associated with a reduction in hospitalisation and surgery in children with Inflammatory Bowel Disease
P-111	Sahana	Shankar	India	Non-invasive assessment of efficacy of exclusive enteral nutrition using composite score of faecal calprotectin, CRP, weighted PCDAI and Mucosal Inflammation Non-invasive Index (MINI) in Paediatric Crohn's disease – the Indian experience
P-112	Zakhar	Shchomak	Portugal	10 Years of Biological Therapy in Paediatric Inflammatory Bowel Disease: experience from a tertiary centre
P-113	Dror	Shouval	Israel	Moderate Correlation between Nancy Histopathology Index and Clinical, Laboratory and Endoscopic Indices of Disease Activity in Pediatric Patients with Ulcerative Colitis
P-116	Lorraine	Stallard	Canada	Higher infliximab dosing is associated with superior drug durability and clinical outcomes in VEO-IBD - a retrospective cohort study
P-117	Eytan	Wine	Canada	ONE-YEAR OUTCOMES WITH USTEKINUMAB THERAPY IN PAEDIATRIC CROHN'S DISEASE: A MULTICENTER COHORT STUDY
P-118	Marta	Tavares	Portugal	Early inflammatory bowel disease in a Portuguese Tertiary Center
P-119	Marta	Tavares	Portugal	Opportunistic infections in paediatric inflammatory bowel disease: the 12-year experience of a tertiary paediatric hospital
P-120	Marta	Tavares	Portugal	TREATMENT OF INFLAMMATORY BOWEL DISEASE IN PAEDIATRIC AGE: WHAT ABOUT ADVERSE REACTIONS?

Posters

P-122	Dan	Turner	Israel	Formatting and validation of the TUMMY-UC, a patient-reported outcome in paediatric ulcerative colitis: a multicenter prospective study
P-123	Darja	Urlep	Slovenia	A novel partial enteral nutrition protocol is effective in inducing clinical and endoscopic remission in active paediatric Crohn's disease
P-124	Elisabeth	Degreef	Belgium	A systematic review on clinical outcomes in paediatric inflammatory bowel disease patients
P-125	Bruno	Hauser	Belgium	The use of nutrition as a therapeutic strategy in children and adolescents with Crohn's disease in Belgium.
P-126	Shezad	Saeed	USA	ENTERAL NUTRITION AS PRIMARY THERAPY OF PEDIATRIC INFLAMMATORY BOWEL DISEASE IN THE USA.
P-127	Marta	Velasco Rodríguez-Belvís	Spain	The effects of inflammatory bowel disease on caregivers: absenteeism and job presenteeism. A SEGHP multicenter study (Spanish Society of Pediatric Gastroenterology, Hepatology and Nutrition)
P-128	Marta	Velasco Rodríguez-Belvís	Spain	Health-related quality of life in a pediatric population affected by Inflammatory Bowel Disease. A SEGHP multicenter study (Spanish Society of Pediatric Gastroenterology, Hepatology and Nutrition)
P-129	Charlotte M.	Verburgt	Netherlands	Personalised Azithromycin+Metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's Disease (CD): initial results of a pilot feasibility study
P-131	Yael	Weintraub	Israel	Sex and sexuality in IBD - the pediatric gastroenterologists' point of view
P-133	Lisa	Parkinson McGraw	Canada	Unpacking the different popular diets for paediatric Crohn's Disease - concerns around nutritional adequacy
P-134	Kay	Crook	United Kingdom	Development of Framework for Professional Practice (FPP) for nurses working in Inflammatory Bowel Disease in adult and paediatric care settings

Posters

P-135	Konstantinos	Gkikas	United Kingdom	The fibre fermentative capacity of the gut microbiota is diminished in children with Crohn's disease and it is independent of disease activity or treatment with exclusive enteral nutrition.
P-136	Konstantinos	Gkikas	United Kingdom	YouTube as a source of Food, Diet-Related Items and Advisory Comments for the management of Inflammatory bowel disease
P-137	Jennifer	Haskett	Canada	Polymeric formulas are effective for induction of remission in paediatric Crohn's disease: are all polymeric formulas equal?
P-138	Marta	Kotkowicz-szczur	Poland	The influence of the Covid-19 epidemic on access to medical advice for children with Inflammatory Bowel Disease (IBD), based on patients with The Children's Memorial Health Institute, Warsaw (IPCZD)
P-139	Martha	van Gaalen	Netherlands	Transition readiness in adolescents with IBD; Translation and Validation of the Transition Readiness Assessment Questionnaire (TRAQ-NL)
P-140	Fevronia	Kiparissi	United Kingdom	A Review of the Psychological Needs of Patients with Inflammatory Bowel Disease within a Specialist Paediatric Gastroenterology Department
P-141	Ana	Lozano Ruf	Spain	ASSOCIATION OF PAEDIATRIC INFLAMMATORY BOWEL DISEASE AND CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS: OUR EXPERIENCE
P-142	Nóra Judit	Béres	Hungary	Biologic treatment after liver transplantation
P-143	Ana	Lozano Ruf	Spain	Crohn's Disease in Niemann–Pick Disease Type C
P-144	Michael	Friedt	Germany	A novel mutation (c.311G>C;p.Trp104Ser) in the ARPC1B gene causing vasculitis, immunodeficiency and very early onset inflammatory bowel disease (VEOIBD) – red flags for reassessment
P-145	Ana	Lozano Ruf	Spain	Paradoxical cutaneous reactions to Anti TNF-α in paediatric patients with inflammatory bowel disease: Experience in our unit.

Posters

P-146	Laura	Gianolio	Italy	Severe refractory Crohn's Disease with autoimmune hepatitis responsive to thalidomide
P-147	Maya	Granot	Israel	EBV positive mucocutaneous ulcer (EBVMCU) in pediatric Crohn's disease - the importance of pathology
P-148	Aditya Kumar	Gupta	India	Matched Unrelated Donor HSCT as curative modality for very early onset IBD caused by IL-10 RB defect
P-149	Keinosuke	Hizuka	Japan	Case report of a paediatric patient with chronic gastroduodenitis owing to 14q13.1q21.1 deletion
P-150	Zilola	Khadjieva	Uzbekistan	Title: Nutritional support of Ulcerative colitis case with 5-aminosalicylic acid (5-ASA) combined therapy
P-151	Chetan	Mandelia	United States	De novo pediatric ulcerative colitis triggered by SARS-CoV-2 infection: A tale of 2 sisters
P-152	Manal	Morgan	Australia	An open study of outcomes in Paediatric Acute Severe Colitis and empiric use of PRASCO antibiotic cocktail
P-153	Manal	Morgan	Australia	An audit of Acute Severe Colitis outcomes in children in the modern era of accelerated Infliximab (IFX)
P-154	Mohana	Sathiaseelan	Australia	Infliximab Monotherapy for Treatment of Diffuse Enteritis Following Colectomy for Ulcerative Colitis in a 14 year old Boy
P-155	Ryutaro	Saura	Japan	Acute disseminated encephalomyelitis associated with very early onset IBD during infliximab therapy
P-156	Valentina	Silvera	Italy	Hidradenitis suppurativa and Crohn's disease: a challenging management



Posters

P-157	Yael	Weintraub	Israel	A possible association between new-onset blepharitis and anti-tumor necrosis factor therapy in patients with Crohn's disease: a case series.
--------------	------	-----------	--------	---
